Friday, March 20, 2026 10:43:28 AM
Recent HCWB News
- HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum • GlobeNewswire Inc. • 04/30/2026 08:20:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/30/2026 04:15:11 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 03:24:37 PM
- HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors • GlobeNewswire Inc. • 04/27/2026 11:30:00 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 04/24/2026 09:30:12 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/23/2026 09:12:45 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 09:23:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 08:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 09:12:29 PM
- HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 03/31/2026 09:05:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 12:00:07 PM
- HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic • GlobeNewswire Inc. • 03/17/2026 11:50:00 AM
- HCW Biologics highlights positive findings for CAR-T therapy manufacturing • IH Market News • 03/16/2026 02:31:28 PM
- HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances • GlobeNewswire Inc. • 03/16/2026 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/13/2026 08:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 01:08:36 PM
- HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 09:43:57 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/19/2026 08:46:38 PM
- HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules • GlobeNewswire Inc. • 02/18/2026 02:50:56 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/17/2026 02:09:25 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/13/2026 09:04:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 01:38:42 PM
- HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune • GlobeNewswire Inc. • 02/13/2026 01:30:00 PM






